-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[ Market analysis of chemical machinery and equipment network ] In recent years, in the context of China's residents' consumption upgrade and increased health awareness, the demand for domestic biological drugs has expanded, and the market has grown rapidly.
Aiming at the blue ocean of the market, more and more domestic biopharmaceutical products have been approved for commercialization, but at the same time, capacity supply has become a major bottleneck.
Chemical machinery and equipment network market analysis chemical machinery and equipmentAiming at the blue ocean of the market, more and more domestic biopharmaceutical products have been approved for commercialization, but at the same time, capacity supply has become a major bottleneck.
Limited capacity has become a bottleneck for domestic biologics growth
Limited capacity has become a bottleneck for domestic biologics growthAccording to Frost & Sullivan’s forecast, the size of the biopharmaceutical market in 2030 is expected to reach 665.
1 billion U.
S.
dollars, and the compound annual growth rate from 2018 to 2030 is expected to be about 8%.
As far as domestic biopharmaceuticals are concerned, with the improvement of the consumption level of Chinese residents and the enhancement of health awareness, the domestic demand for biopharmaceuticals continues to expand, which will drive the rapid development of the domestic biopharmaceutical market.
According to forecasts, the size of my country's biopharmaceutical market will reach 1319.
8 billion yuan by 2030, and the compound annual growth rate from 2018 to 2030 is expected to be about 14%.
1 billion U.
S.
dollars, and the compound annual growth rate from 2018 to 2030 is expected to be about 8%.
As far as domestic biopharmaceuticals are concerned, with the improvement of the consumption level of Chinese residents and the enhancement of health awareness, the domestic demand for biopharmaceuticals continues to expand, which will drive the rapid development of the domestic biopharmaceutical market.
According to forecasts, the size of my country's biopharmaceutical market will reach 1319.
8 billion yuan by 2030, and the compound annual growth rate from 2018 to 2030 is expected to be about 14%.
Biosimilar drugs refer to therapeutic biological products that are similar to the original drug (reference drug) that has been approved for registration in terms of quality, safety and effectiveness.
In recent years, my country’s biosimilar drugs have flourished, and their share of biological drugs is The proportion of will continue to increase, and the potential market will be huge in the future.
In recent years, my country’s biosimilar drugs have flourished, and their share of biological drugs is The proportion of will continue to increase, and the potential market will be huge in the future.
2019 is the first year of biosimilar drugs in China, and domestic biosimilar products such as rituximab injection, adalimumab injection, adalimumab injection, bevacizumab injection, etc.
have been approved for marketing.
.
At the same time, from the perspective of biosimilar drug research and development pipelines, China currently has the majority of research projects, which have exceeded 390, with nearly 180 companies deployed, and competition on the track is becoming increasingly fierce.
have been approved for marketing.
.
At the same time, from the perspective of biosimilar drug research and development pipelines, China currently has the majority of research projects, which have exceeded 390, with nearly 180 companies deployed, and competition on the track is becoming increasingly fierce.
It is worth mentioning that while more and more domestic biopharmaceutical products are beginning to be commercialized, capacity supply is a major bottleneck.
Take Fuhong Hanlin's rituximab biosimilar drug "Han Likang" as an example.
The product was approved for marketing in February 2019 and was officially commercialized in May of that year.
But Han Likang's total sales in 2019 is only 190 million yuan, which is slightly behind the sales of several domestic PD-1s.
It is reported that this is mainly related to Han Likang's current capacity supply, and market demand exceeds demand, which has affected Han Likang's sales volume.
Take Fuhong Hanlin's rituximab biosimilar drug "Han Likang" as an example.
The product was approved for marketing in February 2019 and was officially commercialized in May of that year.
But Han Likang's total sales in 2019 is only 190 million yuan, which is slightly behind the sales of several domestic PD-1s.
It is reported that this is mainly related to Han Likang's current capacity supply, and market demand exceeds demand, which has affected Han Likang's sales volume.
The industry believes that with the entry of more biotechnology companies, the domestic biopharmaceutical market will be a battle for production capacity in the future.
In the context of fierce market competition, domestic biopharmaceutical companies can only become more capable in the market if they break the bottleneck of production capacity.
Competitiveness.
It is reported that in order to break through the bottleneck of production capacity, Fosun Pharma’s supplementary application was approved to increase the production scale of the original solution 2000L and the production equipment of 2000L, which can increase the overall usable production capacity to 14000L, which can provide a strong guarantee for Han Likang and its upcoming products.
In 2020, Han Likang is expected to increase the volume quickly.
In the context of fierce market competition, domestic biopharmaceutical companies can only become more capable in the market if they break the bottleneck of production capacity.
Competitiveness.
It is reported that in order to break through the bottleneck of production capacity, Fosun Pharma’s supplementary application was approved to increase the production scale of the original solution 2000L and the production equipment of 2000L, which can increase the overall usable production capacity to 14000L, which can provide a strong guarantee for Han Likang and its upcoming products.
In 2020, Han Likang is expected to increase the volume quickly.
Urgent need to expand the production capacity of biological equipment
Urgent need to expand the production capacity of biological equipment Faced with the challenge of capacity expansion of biopharmaceutical companies, the upstream bioequipment industry has continued to grow in demand.
At the same time, expanding the production capacity of bioequipment has also become a major issue facing pharmaceutical companies.
At the same time, expanding the production capacity of bioequipment has also become a major issue facing pharmaceutical companies.
In order to support the rapid growth of China's biopharmaceutical industry, pharmaceutical companies are obliged to provide more satisfactory products and services.
For example, Tofflon announced a few days ago that the company expects to invest 500 million yuan in the construction of a biopharmaceutical system equipment industrialization project.
The first phase of the investment is 350 million yuan.
It is planned to be put into operation in 3 years and reach production in 5 years, with an annual output value of 5 billion yuan.
More than 100 million yuan.
The company stated that the construction of this project will help the company expand its bio-equipment manufacturing capacity and further enhance its overall bio-engineering solution capabilities.
For example, Tofflon announced a few days ago that the company expects to invest 500 million yuan in the construction of a biopharmaceutical system equipment industrialization project.
The first phase of the investment is 350 million yuan.
It is planned to be put into operation in 3 years and reach production in 5 years, with an annual output value of 5 billion yuan.
More than 100 million yuan.
The company stated that the construction of this project will help the company expand its bio-equipment manufacturing capacity and further enhance its overall bio-engineering solution capabilities.
What needs attention is that there is still a significant gap between domestic biopharmaceutical equipment and imported equipment.
Domestic equipment is mostly concentrated in the low-end market, while imported manufacturers basically occupy an important market share.
Some pharmaceutical people have said that 90% of the biopharmaceutical equipment used by their companies is currently imported.
Therefore, under the background that domestic biopharmaceuticals bring good opportunities to the equipment industry, domestic biopharmaceutical equipment also needs to strengthen innovation and research and development to break the situation where core technology is limited by people.
Domestic equipment is mostly concentrated in the low-end market, while imported manufacturers basically occupy an important market share.
Some pharmaceutical people have said that 90% of the biopharmaceutical equipment used by their companies is currently imported.
Therefore, under the background that domestic biopharmaceuticals bring good opportunities to the equipment industry, domestic biopharmaceutical equipment also needs to strengthen innovation and research and development to break the situation where core technology is limited by people.
In addition, whether it is to increase production capacity or improve existing equipment, complete solutions and support services can greatly reduce the total cost of pharmaceutical companies and the drug launch process, and increase productivity to a greater extent.
Therefore, from a single biopharmaceutical equipment supplier to the overall equipment The transformation and upgrading of solution providers is also a major development trend in the biological equipment industry.
Therefore, from a single biopharmaceutical equipment supplier to the overall equipment The transformation and upgrading of solution providers is also a major development trend in the biological equipment industry.
Original title: Limited production capacity has become a bottleneck for the growth of domestic biopharmaceuticals, and it is urgent to expand equipment production capacity
